Bristol Myers Squibb Signs Licensing Deal with Avidity Biosciences for Multiple Cardiovascular Targets
By Shweta Gupta
Pharma Deals Review: Vol 2023 Issue 12 (Table of Contents)
Published: 13 Dec-2023
DOI: 10.3833/pdr.v2023.i12.2843 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In order to strengthen its cardiovascular portfolio, Bristol Myers Squibb (BMS) has entered into a development and commercialisation agreement with Avidity Biosciences to create RNA-based medicines for cardiovascular diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS